[SCHEDULE 13D/A] LAVA Therapeutics NV SEC Filing

Rhea-AI Filing Summary

Amendment No. 2 to a Schedule 13D reports that certain Versant-affiliated reporting persons amended prior Schedule 13D disclosures for LAVA Therapeutics N.V. (Common Shares). The filing states that on September 19, 2025 Versant Venture Capital VI, L.P. sold 2,370,533 common shares at a weighted average price of $1.4014 per share for aggregate proceeds of approximately $3,322,064.95, and Versant Vantage I, L.P. sold 532,870 common shares at the same weighted average price for proceeds of approximately $746,764.02. As of that date the reporting persons ceased to beneficially own more than 5% of the issuer's outstanding common shares. The amendment incorporates prior Schedule 13D information not changed by this filing.

Positive

• Transparent disclosure of share sales and aggregate proceeds for each selling entity
• Compliance with SEC rules through amendment to prior Schedule 13D and attestation signatures

Negative

• Material disposition of shares: 2,370,533 and 532,870 shares sold on September 19, 2025
• Reporting persons no longer beneficially own more than 5% of the issuer following the sales

Insights

Financial Analyst

TL;DR Versant entities sold material blocks of LVTX stock on September 19, 2025 and now report ownership below 5%.

The filing documents two disclosed sales: 2,370,533 shares by Versant Venture Capital VI, L.P. and 532,870 shares by Versant Vantage I, L.P., each at a weighted average price of $1.4014. Aggregate proceeds reported are approximately $3.32 million and $746.8 thousand respectively. The reporting persons amend prior Schedule 13D information and state they no longer beneficially own more than 5% of LAVA Therapeutics. For investors, the record is a clear ownership reduction and formal disclosure compliance; the filing does not include rationale for the sales or post-sale ownership figures beyond the below-5% statement.

Corporate Governance Expert

TL;DR Amendment records disclosed disposition of shares and confirms reporting persons fell below 5% ownership threshold.

The amendment updates the Schedule 13D to reflect the September 19, 2025 sales and incorporates unchanged prior disclosures. Signatures show Max Eisenberg attesting on behalf of multiple Versant entities. The filing fulfills disclosure obligations under the Exchange Act by reporting the transactions and the change in beneficial ownership status. The document does not provide any governance actions or agreements tied to the transfers.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

LAVA Therapeutics N.V.

(Name of Issuer)

Common Shares, par value Euro 0.12 per share

(Title of Class of Securities)

N51517105

(CUSIP Number)

Max Eisenberg
One Sansome Street, Suite 1650,
San Francisco, CA, 94104
415-801-8100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/19/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. N51517105

1

Name of reporting person

Versant Venture Capital VI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. N51517105

1

Name of reporting person

Versant Ventures VI GP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. N51517105

1

Name of reporting person

Versant Ventures VI GP-GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. N51517105

1

Name of reporting person

Versant Vantage I, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. N51517105

1

Name of reporting person

Versant Vantage I GP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. N51517105

1

Name of reporting person

Versant Vantage I GP-GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Shares, par value Euro 0.12 per share
(b)	Name of Issuer: LAVA Therapeutics N.V.
(c)	Address of Issuer's Principal Executive Offices: Yalelaan 62, Utrecht, NETHERLANDS , 3584 CM.
Item 1 Comment: This Amendment No. 2 (this "Amendment") amends and supplements the Schedule 13D originally filed by the Reporting Persons with the Commission on April 8, 2021 and amendment No. 1 that was filed with the Commission on September 18, 2025 (collectively, the "Original Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
(b)	See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
(c)	On September 19, 2025, Versant VI sold 2,370,533 Common Shares at a weighted average price per share of $1.4014 for aggregate proceeds of approximately $3,322,064.95. On September 19, 2025, Vantage LP sold 532,870 Common Shares at a weighted average price per share of $1.4014 for aggregate proceeds of approximately $746,764.02.
(e)	As of September 19, 2025, the Reporting Persons ceased to beneficially own more than 5% of the Issuer's outstanding Common Shares.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Versant Venture Capital VI, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P.
Date:	09/23/2025

Versant Ventures VI GP, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P.
Date:	09/23/2025

Versant Ventures VI GP-GP, LLC

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P.
Date:	09/23/2025

Versant Vantage I, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the GP of Versant Vantage I GP, L.P., the GP of Versant Vantage I, L.P.
Date:	09/23/2025

Versant Vantage I GP, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the GP of Versant Vantage I GP, L.P., the GP of Versant Vantage I, L.P.
Date:	09/23/2025

Versant Vantage I GP-GP, LLC

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the GP of Versant Vantage I GP, L.P., the GP of Versant Vantage I, L.P.
Date:	09/23/2025

FAQ

What did the Schedule 13D/A for LAVA Therapeutics (LVTX) disclose?

The amendment discloses that Versant entities sold common shares on September 19, 2025 and now cease to beneficially own more than 5% of LAVA Therapeutics.

How many shares did Versant Venture Capital VI, L.P. sell and for how much?

Versant Venture Capital VI, L.P. sold 2,370,533 common shares at a weighted average price of $1.4014 per share for aggregate proceeds of approximately $3,322,064.95.

How many shares did Versant Vantage I, L.P. sell and for how much?

Versant Vantage I, L.P. sold 532,870 common shares at a weighted average price of $1.4014 per share for aggregate proceeds of approximately $746,764.02.

Does the filing state the reporting persons' current ownership percentage?

The filing states that as of September 19, 2025 the reporting persons ceased to beneficially own more than 5% of the issuer's outstanding common shares; no specific post-sale percentage is provided.

Who signed the amendment on behalf of the reporting persons?

The amendment is signed by Max Eisenberg, COO of related Versant GP entities, attesting to the completeness and accuracy of the statement.